Drug Trial Radar · NCT04218084
Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease
Last checked: Nov 20, 2026Latest source record: Mar 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
236
Actual
Start
Nov 11, 2020
Primary completion
Jan 18, 2024
Study completion Nov 6, 2024
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jan 6, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 14 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a Phase 3, randomized, double-blind, placebo-controlled study of voxelotor in pediatric participants, aged ≥ 2 to \< 15 years old, with Sickle Cell Disease. The primary objective is to evaluate the effect of voxelotor on the TCD (Transcranial Doppler Ultrasound) measurements in SCD participants in this age range.
Conditions
- Sickle Cell Disease
Interventions
VoxelotorDrug
Participants are randomized 1:1 to receive voxelotor or placebo.
PlaceboDrug
Matching placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Time-Averaged Maximum of Mean Velocity (TAMMV) Arterial Cerebral Blood Flow at Week 24Time frame: Baseline (value at screening), Week 24
Locations
35 sites in 9 countries. Site status is shown where the registry gives one.
Children's National Medical Center
Washington D.C., District of Columbia
University of Miami
Miami, Florida
Children's Healthcare of Atlanta: Hughes Spalding
Atlanta, Georgia
Boston Children's Hospital - Clinical Research Pharmacy
Boston, Massachusetts
Boston Children's Hospital
Boston, Massachusetts
University of Mississippi Medical Center
Jackson, Mississippi
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Medical University of South Carolina: Investigational Drug Services
Charleston, South Carolina
Medical University of South Carolina: Shawn Jenkins Women's and Children's Hospital
Charleston, South Carolina
Medical University of South Carolina
Charleston, South Carolina
Texas Children's Hospital - Investigational Pharmacy
Houston, Texas
Texas Children's Hospital- Wallace Tower
Houston, Texas
Texas Children's Hospital
Houston, Texas
Alexandria Clinical Research Center, Faculty of Medicine, Alexandria University
Alexandria, Egypt
Abu El Rich Hospital, Cairo University Hospital
Cairo, Egypt
Ain Shams University Hospital- Clinical Research Center (MASRI)
Cairo, Abassia, Egypt
Zagazig University Hospital
Zagazig, Alsharkia, Egypt
Komfo Anokye Teaching Hospital
Kumasi, Ashanti Region, Ghana
Department of Child Health, University of Ghana Medical School, College of Health Sciences, Korle-Bu
Accra, Greater Accra Region, Ghana
Azienda Ospedaliera Universitaria Meyer "A.O.U. Meyer" - SOC "Oncologia, Ematologia e TCSE"
Florence, Italy
Azienda Ospedaliera Universitaria (A.O.U.) "Luigi Vanvitelli"
Naples, Italy
Azienda Ospedaliera Universita' (AOU ) Padova
Padova, Italy
Azienda Ospedaliera Universita' (AOU) Padova
Padova, Italy
KEMRI CRDR Clinical Research Annex
Nairobi, Kenya
Strathmore University Medical Centre
Nairobi, Kenya
Gertrude's Children Hospital
Nairobi, Kenya
Kemri/Crdr,Siaya,Kemri Clinical Research Annex
Kisumu, Siaya County, Kenya
University of Nigeria Teaching Hospital
Enugu, Nigeria
Barau Dikko Teaching/Kaduna State University
Kaduna, Nigeria
Aminu Kano Teaching Hospital
Kano, Nigeria
Lagos University Teaching Hospital
Surulere, Lagos, Nigeria
College of Medicine, University of Ibadan
Ibadan, Oyo State, Nigeria
Sultan َQaboos University Hospital
Muscat, Oman
King Abdullah International Medical Research Center (KAIMRC), Ministry of National Guard - Health
Riyadh, Saudi Arabia
Barts Health NHS Trust
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.